Common Off-Label Uses for Ivermectin
Ivermectin is FDA-approved only for intestinal strongyloidiasis and onchocerciasis, but is commonly used off-label for various parasitic infections in humans and animals, as well as for dermatologic conditions including scabies, head lice, rosacea, and Demodex-related conditions 1.
FDA-Approved Indications (Not Off-Label)
- Strongyloidiasis of the intestinal tract (nondisseminated)
- Onchocerciasis (river blindness) caused by Onchocerca volvulus 1
Established Off-Label Uses in Humans
Parasitic Infections
Ivermectin is widely used off-label for numerous parasitic infections beyond its FDA-approved indications 2. The drug demonstrates broad-spectrum antiparasitic activity against roundworms and arthropod infestations 3.
Dermatologic Conditions
Scabies: This represents one of the most common and well-supported off-label uses. Evidence demonstrates both safety and efficacy, including in vulnerable populations:
- Pediatric scabies: A multicentric study of 170 infants and children weighing 4-14.5 kg (ages 1-64 months) showed only 4% mild adverse events with 85% healing rates 4
- Optimal dosing appears to be >200 μg/kg with a second dose administered <10 days after the first 4
- Particularly valuable when topical treatments are poorly tolerated 4
Head lice: Used off-label with documented low rates of adverse events 5
Rosacea: While ivermectin has received FDA approval for inflammatory lesions of rosacea in adults, it was initially used off-label for this indication based on its anti-inflammatory and anti-Demodex activity 5
Demodex-related conditions:
- Blepharitis
- Demodicidosis These uses are based on ivermectin's activity against Demodex mites 5
Veterinary Off-Label Uses
In veterinary medicine, ivermectin is used off-label for many worm-related parasitic diseases, particularly in domestic animals, beyond its licensed indications 3.
Experimental/Investigational Areas (Not Recommended for Clinical Use)
COVID-19: This warrants special attention due to widespread misuse:
- Do not use ivermectin for COVID-19 treatment - both major guidelines strongly recommend against this practice 6, 2
- The IDSA provides a strong recommendation against use in ambulatory COVID-19 patients (moderate certainty evidence) and suggests against use in hospitalized patients (conditional recommendation, very low certainty evidence) 2
- The American College of Physicians reaffirms that ivermectin use is not supported for COVID-19 6
- A 2024 meta-analysis of 12 RCTs with 7,035 participants found ivermectin did not reduce hospitalization, mortality, adverse events, mechanical ventilation, or clinical worsening in non-hospitalized COVID-19 patients 7
- While in vitro activity exists, concentrations required exceed those achievable in human plasma and lung tissue 2
Other experimental areas mentioned in research but lacking clinical evidence:
Critical Safety Considerations
Veterinary product misuse: During COVID-19, substantial numbers of people consumed veterinary ivermectin products off-label 9. This practice is strongly discouraged because:
- Veterinary dosages and regimens are designed for animals and can cause serious adverse events in humans
- Products may contain untested excipients and secondary actives (e.g., clorsulon) with unknown long-term health impacts in humans 9
Pediatric dosing: When used off-label in children <15 kg, doses >200 μg/kg with appropriate timing between doses optimize efficacy 4
General safety profile: Ivermectin's inability to cross the blood-brain barrier in mammals and high affinity for invertebrate neuronal ion channels contributes to its favorable safety profile when used appropriately 5
Clinical Bottom Line
The legitimate off-label uses of ivermectin center primarily on parasitic infections and specific dermatologic conditions where evidence supports efficacy and safety. Healthcare providers should actively discourage use for COVID-19 and other conditions lacking clinical evidence, while recognizing established off-label uses for scabies, head lice, and Demodex-related conditions have reasonable supporting data 5, 4.